Updates in the management of diabetic macular edema

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Mathew, Christopher ^a   Yunirakasiwi, Anastasia ^a   Sanjay, Srinivasan ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KHOO TECK PUAT HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FENOFIBRIC ACID; GLITAZONE DERIVATIVE; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB;

DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIAGNOSTIC IMAGING; DISEASE SEVERITY; HUMAN; INFLAMMATION; LASER COAGULATION; MICROANEURYSM; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA EXUDATE; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT INDICATION; VITRECTOMY; DIABETIC RETINOPATHY; MACULAR EDEMA; PROCEDURES;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETIC RETINOPATHY; HUMANS; LIGHT COAGULATION; MACULAR EDEMA; RANIBIZUMAB;

EID: 84929379983     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/794036     Document Type: Review

References (47)

1. J. Bali and R. T. Bali, "Pathological ocular angiogenesis in diabetes: a perspective of emerging paradigms and current evidence, " Journal of Clinical Ophthalmology and Research, vol. 1, no. 1, pp. 3-10, 2013.
2. "Photocoagulation for diabeticmacular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study group, " Archives of Ophthalmology, vol. 103, no. 12, pp. 1796-1806, 1985.
3. D. N. Koleva-Georgieva and N. P. Sivkova, "Types of diabetic macular edema assessed by optical coherence tomography, " Folia medica, vol. 50, no. 3, pp. 30-38, 2008.
4. S. W. Kang, C. Y. Park, andD.-I. Ham, "The correlationbetween fluorescein angiographic and optical coherence tomographic features in clinically significant diabeticmacular edema, " American Journal of Ophthalmology, vol. 137, no. 2, pp. 313-322, 2004.
5. "Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study research group, " Ophthalmology, vol. 98, supplement, no. 5, pp. 807-822, 1991.
6. D. A. Dmuchowska, P. Krasnicki, and Z. Mariak, "Can optical coherence tomography replace fluorescein angiography in detection of ischemic diabetic maculopathy?" Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 5, pp. 731-738, 2014.
7. J. Ding and T. Y. Wong, "Current epidemiology of diabetic retinopathy and diabetic macular edema, " Current Diabetes Reports, vol. 12, no. 4, pp. 346-354, 2012.
8. G. E. Lang, "Diabetic macular edema, " Ophthalmologica, vol. 227, supplement 1, pp. 21-29, 2012.
9. N. Bhagat, R. A. Grigorian, A. Tutela, and M. A. Zarbin, "Diabetic macular edema: pathogenesis and treatment, " Survey of Ophthalmology, vol. 54, no. 1, pp. 1-32, 2009.
10. Y. G. Park, E. Y. Kim, and Y. J. Roh, "Laser-based strategies to treat diabetic macular edema: history and new promising therapies, " Journal of Ophthalmology, vol. 2014, Article ID 769213, 9 pages, 2014.
11. J. Roider, S. H. M. Liew, C. Klatt et al., "Selective retina therapy (SRT) for clinically significant diabeticmacular edema, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 9, pp. 1263-1272, 2010.
12. G. P. Giuliari, D. A. Guel, and V. H. Gonzalez, "Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema, " Current Diabetes Reviews, vol. 5, no. 1, pp. 33-38, 2009.
13. M. Rinaldi, F. Chiosi, R. dell'Omo et al., "Intravitrealpegaptanib sodium (Macugen) for treatment of diabetic macular oedema: a morphologic and functional study, " British Journal of Clinical Pharmacology, vol. 74, no. 6, pp. 940-946, 2012.
14. R. Rajendram, S. Fraser-Bell, A. Kaines et al., "A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-Month data: report 3, " Archives of Ophthalmology, vol. 130, no. 8, pp. 972-979, 2012.
15. D. V. Do, Q. D. Nguyen, A. A. Khwaja et al., "Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment, " JAMA Ophthalmology, vol. 131, no. 2, pp. 139-145, 2013.
16. P. S. Muether, K. M. Droege, and S. Fauser, "Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab, " British Journal of Ophthalmology, vol. 98, no. 2, pp. 179-181, 2014.
17. M. J. Elman, L. P. Aiello, R. W. Beck et al., "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, " Ophthalmology, vol. 117, no. 6, pp. 1064. e35-1077. e35, 2010.
18. G. Barteselli, I. Kozak, S. El-Emam, J. Chhablani, M. A. Cortes, and W. R. Freeman, "12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation, " British Journal of Ophthalmology, vol. 98, no. 8, pp. 1036-1041, 2014.
19. P. A. Pearson, T. L. Comstock, M. Ip et al., "Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial, " Ophthalmology, vol. 118, no. 8, pp. 1580-1587, 2011.
20. Y. Takamura, T. Tomomatsu, T. Matsumura et al., "The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection, " Investigative Ophthalmology & Visual Science, vol. 55, no. 8, pp. 4741-4746, 2014.
21. N. Erol, H. Gursoy, S. Kimyon, S. Topbas, andE. Colak, "Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema, " Advances inTherapy, vol. 29, no. 4, pp. 359-369, 2012.
22. S. Ghosh, J. Dutta, S. Mukhopadhyay, and G. Bhaduri, "Correlation of macular thickness and posterior hyaloid change following bevacizumab and triamcinolone in diffuse diabeticmacular edema in middle-aged patients, " International Ophthalmology, vol. 31, no. 5, pp. 363-368, 2011.
23. R. W. Beck, A. R. Edwards, L. P. Aiello et al., "Three-year followup of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabeticmacular edema, " JAMA Ophthalmology, vol. 127, no. 3, pp. 245-251, 2009.
24. Diabetic Retinopathy Clinical Research Network, "A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema, " Ophthalmology, vol. 115, no. 9, pp. 1447. e10-1459. e10, 2008.
25. K. Sonmez, T. H. Tezel, and H. J. Kaplan, "The role ofmacular hydration in the evaluation of the effect of intravitreal triamcinolone on visual acuity in eyes with diabetic macular edema, " International Ophthalmology, vol. 33, no. 1, pp. 15-25, 2013.
26. A. Martidis, J. S. Duker, P. B. Greenberg et al., "Intravitreal triamcinolone for refractory diabetic macular edema, " Ophthalmology, vol. 109, no. 5, pp. 920-927, 2002.
27. M. C. Gillies, L. L. Lim, A. Campain et al., "A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema (BEVORDEX), " Ophthalmology, vol. 121, no. 12, pp. 2473-2481, 2014.
28. R. Lazic, M. Lukic, I. Boras et al., "Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant, " Retina, vol. 34, no. 4, pp. 719-724, 2014.
29. A. M. Elbendary and M. M. Shahin, "Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema, " Retina, vol. 31, no. 10, pp. 2058-2064, 2011.
30. P. S. Silva, J. D. Cavallerano, J. K. Sun, L. M. Aiello, and L. P. Aiello, "Effect of systemic medications on onset and progression of diabetic retinopathy, " Nature Reviews Endocrinology, vol. 6, no. 9, pp. 494-508, 2010.
31. J. H. Kim, S. W. Kang, H. S. Ha, and J. R. Kim, "Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema, " Korean Journal of Ophthalmology, vol. 27, no. 3, pp. 186-193, 2013.
32. Y. T. Kim, S. W. Kang, S. J. Kim, S. M. Kim, and S. E. Chung, "Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments: 3-year results, " Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 5, pp. 679-684, 2012.
33. P. A. Campochiaro, R. Channa, B. B. Berger et al., "Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study, " American Journal of Ophthalmology, vol. 155, no. 4, pp. 697-704, 2013.
34. Q. D. Nguyen, R. A. Schachar, C. I. Nduaka et al., "Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabeticmacular edema (the DEGAS study), " Investigative Ophthalmology and Visual Science, vol. 53, no. 12, pp. 7666-7674, 2012.
35. J. Tang, A. A. Herda, and T. S. Kern, "Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema, " British Journal of Ophthalmology, vol. 98, no. 8, pp. 1013-1015, 2014.
36. M. Cellini, N. Balducci, E. Strobbe, and E. C. Campos, "Subtenon injection of natural leukocyte interferon -2a in diabetic macular edema: a case report, " BMC Ophthalmology, vol. 13, no. 1, article 63, 2013.
37. T. M. Diep and I. Tsui, "Risk factors associated with diabetic macular edema, " Diabetes Research and Clinical Practice, vol. 100, no. 3, pp. 298-305, 2013.
38. P. Massin, T. Peto, J. Ansquer, P. Aubonnet, and F. T. Macufen Study Investigators, "Effects of fenofibric acid on diabetic macular edema: theMacuFen study, " Ophthalmic Epidemiology, vol. 21, no. 5, pp. 307-317, 2014.
39. E. A. Friedman, C. D. Brown, and D. H. Berman, "Erythropoietin in diabetic macular edema and renal insufficiency, " American Journal of Kidney Diseases, vol. 26, no. 1, pp. 202-208, 1995.
40. J. Garć?-Arum?, A. Fonollosa, C. Macià et al., "Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema, " Eye, vol. 23, no. 5, pp. 1066-1071, 2009.
41. N. Wang, Z. Zheng, H.-Y. Jin, and X. Xu, "Treatment effects of captopril on non-proliferative diabetic retinopathy, " Chinese Medical Journal, vol. 125, no. 2, pp. 287-292, 2012.
42. E. H. Ryan Jr., D. P. Han, R. C. Ramsay et al., "Diabetic macular edema associated with glitazone use, " Retina, vol. 26, no. 5, pp. 562-570, 2006.
43. S. Matsuda, T. Tam, R. P. Singh et al., "Impact of insulin treatment in diabeticmacular edema therapy in type 2 diabetes, " Canadian Journal of Diabetes, vol. 39, no. 1, pp. 73-77, 2015.
44. V. K. Ajoy Mohan, S. Nithyanandam, and J. Idiculla, "Microalbuminuria and low hemoglobin as risk factors for the occurrence and increasing severity of diabetic retinopathy, " Indian Journal of Ophthalmology, vol. 59, no. 3, pp. 207-210, 2011.
45. L. P. Aiello, M. T. Cahill, and J. S. Wong, "Systemic considerations in the management of diabetic retinopathy, " American Journal of Ophthalmology, vol. 132, no. 5, pp. 760-776, 2001.
46. B. E. K. Klein, R. Klein, and S. E. Moss, "Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?" American Journal of Ophthalmology, vol. 128, no. 5, pp. 652-654, 1999.
47. T. Tokuyama, T. Ikeda, and K. Sato, "Effects of haemodialysis on diabetic macular leakage, " British Journal ofOphthalmology, vol. 84, no. 12, pp. 1397-1400, 2000.